Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-06-12
2007-06-12
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254020, C514S254050, C514S254100, C514S253010, C514S255040, C514S254040, C544S360000, C544S366000, C544S369000, C544S372000, C544S379000, C544S396000
Reexamination Certificate
active
10477642
ABSTRACT:
Compounds of general formula I R1is selected from any one of phenyl, pyridinyl, thienyl, furanyl, imidazolyl, pyrrolyl, triazolyl, thiazolyl, and pyridine N-oxide; R2is independently selected from ethyl and isopropyl; R3is independently selected from hydrogen and fluoro; R4is independently selected from —OH, —NH2and —NHSO2R5; and R5is independently selected from hydrogen, —CF3and C1–C6alkyl, or salts thereof or separate enantiomers and salts thereof; where each R1heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C1–C6alkyl, NO2, CF3, C1–C6alkoxy, chloro, fluoro, bromo, and iodo. The substitutions on the heteroaromatic ring may take place in any position on said ring systems; are disclosed and claimed in the present application, as well as separate enantiomers of the compounds and salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain, anxiety and functional gastrointestinal disorders.
REFERENCES:
patent: 3940386 (1976-02-01), Szabo et al.
patent: 5574159 (1996-11-01), Chang et al.
patent: 5681830 (1997-10-01), Chang et al.
patent: 5807858 (1998-09-01), Chang et al.
patent: 5854249 (1998-12-01), Chang et al.
patent: 6130222 (2000-10-01), Roberts et al.
patent: 6680318 (2004-01-01), Brown et al.
patent: 6680321 (2004-01-01), Roberts et al.
patent: 6696447 (2004-02-01), Brown et al.
patent: 6784181 (2004-08-01), Brown et al.
patent: 7030124 (2006-04-01), Chang et al.
patent: 2006/0142296 (2006-06-01), Brown et al.
patent: 24 31 178 (1975-01-01), None
patent: 29 00 810 (1980-07-01), None
patent: 0 133 323 (1985-02-01), None
patent: 0 166 302 (1986-01-01), None
patent: 0 283 310 (1988-09-01), None
patent: 0 289 227 (1988-11-01), None
patent: 0 624 584 (1994-11-01), None
patent: 2 696 744 (1994-04-01), None
patent: 2 076 403 (1981-12-01), None
patent: 2 210 366 (1989-06-01), None
patent: 7-138230 (1995-05-01), None
patent: WO 86/04584 (1986-08-01), None
patent: WO 91/07967 (1991-06-01), None
patent: WO 92/04338 (1992-03-01), None
patent: WO 9315062 (1993-08-01), None
patent: WO 95/04051 (1995-02-01), None
patent: WO 9723466 (1997-07-01), None
patent: WO 98/28270 (1998-07-01), None
patent: WO 98/28275 (1998-07-01), None
patent: WO 99/33806 (1999-07-01), None
patent: 01/74805 (2001-10-01), None
Nortey et al. Bioorganic & Medicinal Chemistry letters, vol. 11, p. 1741-1743 (2001).
Snyder et al. Trends in Pharmacological Sciences, vol. 24, p. 198-205 (2003).
Bilsky, et al., SNC 80, A Selective, Nonpeptidic and Systemically Active Opioid Delta Agonist, J. Pharmacol. Experi. Ther. 273:359-366(1995).
Takemori, et al., “Selective Natrexone-Drived Opioid Receptor Antagonists,” Annu. Rev. Pharmacol. Toxicol. 32:239-269 (1992).
Bilsky, et al., “Characterization of Enantiomers of (+) BW373U86 and Related Compounds: Highly Selective Non-Peptidic Delta Opioid Agonists,” Reg. Peptides 54:25-26 (1994).
Calderon, et al., “Probes for Narcotic Receptor Mediated Phenomena. 19. Synthesis of . . . Opioid Receptor Agonist,” J. Med. Chem. 37:2125-2128 (1994).
Calderon, et al., “Probes for Narcotic Receptor Mediated Phenomena. 23. Synthesis . . . Opioid Receptor Ligands,” J. Med. Chem. 40:695-704 (1997).
Chang, et al., “A Novel, Potent and Selective Nonpeptidic Delta Opioid Receptor Agonist BW373U86,” J. Pharmacol. Exper. Therap. 267:852-857 (1993).
Katrizky, et al., “Benzotriazole-Mediated Arylalkylation and Heteroarylalkylation,” Chem. Soc. Rev. 23:363-442 (1994).
Kingsbury, et al., “Synthesis of Structural Analogs of Leukotriene B and their Receptor Binding Activity,” J. Med. Chem. 36:3308-3320 (1993).
Lopez, et al., “Exploring the Structure-Activity Relationships . . . Opioid Receptor Nonpeptide Agonist Ligand,” J. Med. Chem. 42:5359-5368 (1999).
Plobeck, et al., “New Diarylmethylpiperazines as Potent and Selective Nonpeptidic Opioid Receptor Agonists with Increased In Vitro Metabolic Stability,” J. Med. Chem. 43:3878-3894 (2000).
Snuggs, et al., “Facile Synthesis of 8-Substituted Quinolines,” J. Org. Chem. 45:1514-1515 (1980).
Zhang, et al., “Probes for Narcotic Receptor Mediated Phenomena. 26. Synthesis . . . Opioid Receptor Ligands,” J. Med. Chem. 42:5455-5463 (1999).
English Abstract for FR 2696744 (Apr. 1994).
English Abstract for DE 2900810 (Jul. 1980).
English Abstract for JP 07138230 (May 1995).
Burkey, et al., “The Efficacy of Delta-Opioid Receptor-Selective Drugs,” Medline Abstract for Life Sci. 62:1531-1536 (1998).
Nagase, et al., “the Pharmacological Profile of Delta Opioid Receitor Ligands, (+) and (−) TAN-67 on Pain Modulation,” Medline Abstract for Life Sci. 68:2227-2231 (2001).
Green, “Protective Groups in Organic Synthesis,” pp. 267-268 and 331 (1981).
Brown William
Plobeck Niklas
Walpole Christopher
AstraZeneca AB
Bernhardt Emily
Cohen Jacqueline M.
LandOfFree
4(phenyl-piperazinyl-methyl) benzamide derivatives and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4(phenyl-piperazinyl-methyl) benzamide derivatives and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4(phenyl-piperazinyl-methyl) benzamide derivatives and their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3807130